Comment from Biotechnology Innovation Organization

Summary: The Biotechnology Innovation Organization (BIO) supports the FDA's draft guidance on safety assessments for genome editing products, praising its forward-looking approach and clarity. They request specific clarifications and refinements regarding biodistribution-driven scope, modality-specific requirements (especially for base and nickase editors), and standardized reporting for chromosomal integrity and variant-aware analysis.